


















HTreatment of Hepatitis C Virus Infection in Kidney Transplant
Recipients: Case Report
F. Caeiro, V. Baptista, N. Rodrigues, D. Carvalho, I. Aires, F. Remédio, and F. Nolasco
ABSTRACT
Chronic hepatitis C virus (HCV) infection exists in a large proportion of patients
undergoing renal transplantation. Nowadays it is not considered to be an absolute
contraindication to transplantation; however, it is associated with an increased risk for the
patient and accounts for a shorter half-life of the renal allograft. We present three
transplant recipients who displayed serious hepatic dysfunction after renal transplantation
due to an HCV infection. In two of these cases, the liver biopsies established the diagnosis
of FCH. In the third case, the liver biopsy was compatible with the early stages of FCH. All
patients were started on peg-interferon alfa 2-b and ribavirin with subsequent normaliza-
tion of hepatic function and early complete viral responses.
p
HHEPATITIS C VIRUS (HCV) infection has a prev-alence of 5% among hemodialysis (HD) patients in
Portugal.1 Renal transplantation remains the best thera-
eutic option for chronic renal failure (CRF)2 despite
he fact that these patients show worse long-term out-
omes due to infectious complications and hepatic fail-
re.3,4 Allograft half-life is also reduced due to chronic
ephropathy, de novo membranoproliferative glomerulo-
ephritis, membranous glomerulonephritis, cryoglobu-
inemia, and an increased risk of development of diabetes
ellitus.5
HCV therapy is seldom used in transplanted patients,
since a cure is only attained in 0% to 50% of cases;
furthermore, few individuals achieve the end of the treat-
ment due to the adverse effects (0%–100%).6 Treatment is
lso associated with an increased risk of acute cellular and
ascular rejection (15%–60%), causing allograft loss in
bout 20% of cases, and rebound of viral load to pretreat-
ent levels after its discontinuation.6 A rejection episode
uring HCV therapy is usually therapy-resistant and irre-
ersible.6
In fact, the only widely accepted indication for HCV
treatment after transplantation is the development of fibro-
sing cholestatic hepatitis (FCH).7 Initially described in 1991
as a complication of a hepatitis B infection (HBV) in liver
transplant recipient,8 this rare entity appears to be associ-
ted with HCV infection in renal transplantation.9 It seems
o be associated with rapid viral replication in the immedi-
te period following transplantation with the development
f rapidly progressive hepatic failure with ensuing death.
erein we have presented three cases of renal transplant
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A 59-year-old male Caucasian patient with CRF of unknown
origin under HD for 68 months, had arterial hypertension and
was HCV (genotype 2) positive since 2002. He was admitted for
deceased donor renal transplantation in October 2007. His
panel-reactive antibody (PRA) content was 98% and showed
one HLA compatibility with the donor. Immunosuppression was
performed with antithymocyte globulin, human immunoglobu-
lin, tacrolimus (FK), mycophenolate mofetil (MMF) and corti-
costeroids (CT). In the immediate period following transplan-
tation, he experienced an acute humoral rejection episode,
which was treated with four courses of immunoglobulin and two
of rituximab. At the time of discharge, he displayed good
allograft function with serum creatinine of 1.2 mg/dL, but he had
developed diabetes mellitus. He did not receive any other blood
derivatives besides immunoglobulin. His maintenance therapy
was FK, MMF, and CT.
During the pretransplant period, he had undergone a normal
abdominal ultrasound and displayed serum levels of alanine amino-
transferase (ALT): 52 U/L; aspartate aminotransferase (AST): 42 U/L:
alkaline phosphatase (ALP): 173 U/L; gamma-glutamyltransferase
(G-GT): 260 U/L; bilirubin: 0.6 mg/dL; total protein: 7.1 g/dL; and
albumin: 4.3 g/dL. Two months after transplantation, we noticed
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260 CAEIRO, BAPTISTA, RODRIGUES ET ALprogressive hepatic dysfunction with AST: 143 U/L; ALT: 120 U/L;
ALP: 173 U/L; G-GT: 260 U/L; and bilirubin: 3.2 mg/dL. Serolo-
gies for cytomegalovirus (CMV) and HBV were negative. A
hepatic biopsy showed a mixed infiltration of the portal area,
hepatic baloonization, and hepatocanalicular cholestasis without
fibrosis, suggesting iatrogenic hepatotoxicity.
We altered the immunosuppression to sirolimus, low-dose FK,
and CT; however, progressive hepatic failure continued. At 3
months after transplantation he had AST: 168 U/L; ALT: 122 U/L;
ALP: 144 U/L; G-GT: 101 U/L, and bilirubin: 20 mg/dL. RNA HCV
viral load was 7.6 106 U/L. We repeated the hepatic biopsy, which
ow showed a mixed inflammatory infiltrate, ductal proliferation,
nd marked cholestasis of the parenchyma and canaliculus with
oderated portal and pericellular fibrosis, aspects characteristic of
CH. He was started on peg-interferon alfa 2-b (PEG IFN -2b; 50
g/wk) and ribavirin (600 mg/d) for 24 weeks. There was a marked
mprovement of hepatic function with AST: 47 U/L; ALT: 28 U/L;
LP: 191 U/L; G-GT: 36 U/L; and bilirubin: 1.1 mg/dL. Allograft
unction was steady with a serum creatinine of 1.2 mg/dL. There
as a complete viral response with an RNA HCV: 615 U/L. One
onth after completion of therapy, a new biopsy revealed HCV
hronic hepatitis with an activity level of 3/18 by the modified
istologic activity index and 5/6 for fibrosis.
One month after finishing HCV therapy, he experienced a bout
f acute humoral rejection with treatment with immunoglobulin. In
pril 2010, at 22 months after finishing therapy, he displayed: AST:
5 U/L; ALT: 38 U/L; ALP: 212 U/L; G-GT: 98 U/L; bilirubin: 0.9
g/dL and serum creatinine: 1.4 mg/dL. Despite this satisfactory
rofile, a viral relapse was discovered 2 months after finishing
herapy. His hemoglobin was stable during the full course of
herapy and there was no need for the introduction of erythropoi-
sis-stimulating agents (ESA).
Case 2
A 40-year-old male Caucasian patient with CRF of unknown
etiology underwent renal substitution therapy for 86 months (6 in
HD and the remaining in peritoneal dialysis). A living donor renal
transplant was performed in September 2009. He presented a PRA
of 0% with one HLA match with the donor. He was started on
thymoglobulin, FK, MMF, and CT. The early posttransplant period
was uneventful and he was discharged with a serum creatinine of
1.5 mg/dL. He did not receive any blood derivative transfusion. In
the pretransplant period, he displayed normal hepatic function
with consistently normal hepatic ultrasounds and negative serolo-
gies for HCV and HBV. His maintenance therapy was FK, MMF,
and CT.
One month after transplantation we noticed alterations in he-
patic function AST: 143 U/L; ALT: 208 U/L; ALP: 826 U/L; G-GT:
92 U/L; and bilirubin: 1.5 mg/dL. At that time, he was negative for
HBV, HCV, and CMV, but the herpes virus 6 serology was a weak
positive He received intravenous acyclovir without improvement.
Two months after transplantation, the hepatic function worsened,
with AST: 750 U/L; ALT: 1116 U/L; ALP: 280 U/L; G-GT: 1126
U/L; and bilirubin: 6.4 mg/dL. The first hepatic biopsy revealed a
mixed inflammatory infiltrate with some eosinophils and focal
hepatocellular necrosis without fibrosis. With the suspicion of
iatrogenic hepatitis, immunosuppression was switched to sirolimus
and prednisolone. However, there was no improvement in hepatic
function. Polymerase chain reaction (PCR) for HCV showed RNA
HCV 7.6  106 U/L, genotype 3a. A new hepatic biopsy showed
mixed portal infiltration with ductal proliferation and cholestasis
associated with pericellular fibrosis leading to the diagnosis ofFCH. We initiated therapy with PEG IFN -2b (50 g/wk) and
ibavirin (600 mg/g). After 24 weeks of therapy, the hepatic
unction was AST: 39 U/L; ALT: 41 U/L; ALP: 96 U/L; G-GT: 24
/L; bilirubin: 0.3 mg/dL; and RNA HCV  615 U/L. He
aintains normal renal function with a serum creatinine of 1.1
g/dL. HCV serologies remain negative with a viral response
ustained at 2 months after finishing therapy. The donor tested
egative for HCV infection by serologic and PCR methods. No
SA therapy was required.
Case 3
A 51-year-old female Caucasian patient with CRF from repeti-
tive bouts of pyelonephritis was under HD treatment for 108
months. At deceased donor renal allograft transplantation in
September 2009, she presented two HLA compatibilities with
the donor and a PRA of 12%. Induction immunosuppression
was performed with basiliximab, FK, MMF, and CT. She
experienced late allograft function after HD dependence for 4
months due to extensive acute tubular necrosis and atheroem-
bolism diagnosed by allograft biopsy. She also experienced an
episode of acute humoral rejection, which was treated with
immunoglobulin. During this period, she received 3 U of
erythrocyte concentrate. The maintenance immunosuppression
was FK, MMF, and CT. Basal serum creatinine was 3.3 mg/dL.
HBV and HCV serologies, abdominal ultrasound, and hepatic
function were normal before transplantation.
On a routine analysis about 3 months after transplantation we
observed hepatic function AST: 142 U/L; ALT: 197U/L; ALP: 177
U/L; G-GT: 137 U/L; and bilirubin: 0.3 mg/dL. Serologies for
HBV, HCV, and CMV were negative. Over the 2 following months,
there was progressive hepatic dysfunction. A liver biopsy showed a
mixed sinusoidal infiltrate with mild cholestasis of the parenchyma
as well as hepatocellular necrosis with some portal fibrosis. The
diagnosis of iatrogenic hepatitis was deemed to be the most
probable, we switched the maintenance therapy to sirolimus and
CT. Despite this change hepatic function continued to deteriorate.
At 5 months after transplantation it was AST: 462 U/L; ALT: 373
U/L; ALP: 569 U/L; G-GT: 1901 U/L; and bilirubin 1.5 mg/dL.
HCV PCR showed 7.6  106 U/L, genotype 3a. She was started
n PEG IFN -2b (50 g/wk) and ribavirin (600 mg/d). Eight weeks
fter starting therapy, the dose of PEG IFN -2b was reduced to 30
g/wk with a slight elevation in serum creatinine (3.7 mg/dL). At
hat time, the viral load was already undetectable (RNA HCV 
15 U/L). After 12 weeks of therapy, she displayed normal hepatic
unction with AST: 26 U/L; ALT: 14 U/L; ALP: 121 U/L; G-GT: 37
/L; and bilirubin: 0.4 mg/dL with unchanged renal function at a
erum creatinine of 3.5 mg/dL. Therapy was discontinued at 14
eeks because of renal dysfunction (creatinine: 4 mg/dL) and
nemia with the need for increased doses of ESA. Four weeks after
nishing therapy, she still has normal hepatic function with AST: 58
/L; ALT: 71 U/L; ALP: 147 U/L; G-GT: 34 U/L; however, she
howed a viral relapse with RNA HCV 1.2  105 U/L.
In our unit, HCV serology is performed using a third-generation,
enzyme-linked imunoassay. All patients received their renal allo-
grafts from HCV negative donors.
DISCUSSION
The development of chronic hepatic disease and cirrhosis is
more frequent in the renal transplant population who






































HCV INFECTION IN LIVER RECIPIENTS 261renal transplantation; it appears to be associated with HCV
with an incidence between 1.5% and 5%.9,10
Among our patients, only the first case was known to be
HCV positive; other two patients did not show anti-HCV
antibodies. Unfortunately, the search for RNA HCV was
not performed on these patients before transplantation, so
it is impossible to determine whether they were in a window
period or whether it was an old infection.
The altered hepatic function occurred between the first
and third month after transplantation with a histological
diagnosis only performed in the second and third month,
which represented the time of peak hepatic dysfunction
(Table 1). In the third patient, we performed only one
biopsy. It was not sufficiently characteristic of FCH to
achieve the diagnosis; the first biopsies of the first two
patients were interpreted as cholestatic lesions from a
probable toxic etiology. This was the reason why there
was a change in maintenance therapy to sirolimus with
suspension or dose reduction of FK. MMF was also
terminated in all patients, and the dose of CT increased.
Once the diagnosis of FCH was established, there is
little doubt about initiating therapy with PEG IFN -2b
nd ribavirin. However, it is important to note that
dverse effects of interferon therapy on allograft survival
re so well established that this treatment is reserved for
atients with FCH where hepatic failure and death are
sual complications.7,9,10 Renal allograft rejection is an
usual complication of interferon therapy that complicates
9% to 100% of cases11 with the greatest scores associated
ith an early start of therapy. It seems that this treatment
s associated with induction of cell surface expression of
LA alloantigens as well as increased antibody produc-
ion by B cells and intracellular cytokine gene expression.
The observed viral load and viral genotypes forecasted a
avorable response to therapy. The first two patients
howed complete viral responses with a negative viral load
nd normalization of hepatic function tests. It is also
mportant to note that both subjects maintained stable renal
unction with no need for the introduction of ESA therapy
Table 2).
The third patient had an impressive initial response to
herapy; however, the renal dysfunction was aggravated
ith consequent anemia requiring discontinuation of ther-
py. These results are, however, difficult to interpret, since
t the start of therapy she already had important renal
ysfunction, which she maintains after discontinuing ther-
py.














Case 1 3 168/122 101/144 20 2
Case 2 2 750/1116 1126/280 6.4 3a
Case 3 5 462/373 1901/569 1.5 3aHCV, hepatitis C Virus; AST, aspartate aminotransferase; GGT, gamma-
glutamyltransferase; ALP, alanine aminotransferase.Only the first patient experienced rejection episodes,
hich occurred 1 month after finishing therapy. The
cute humoral rejection responded to immunoglobulin
herapy. Finally, it is important to note that even the
atients with viral relapses maintained stable hepatic
unction. Since FCH is usually associated with a grim
rognosis, it seems reasonable to begin treatment to
ontrol hepatic damage that results from unchecked viral
eplication in the early posttransplant period during
hich the induction immunosuppressive protocols are
nitiated.
In conclusion, even if treatment of HCV infection after
enal transplantation is not recommended due to the high
isk of rejection, it should be performed when liver failure
s imminent.5,7,12 We showed that treatment is possible with
reservation of both renal and hepatic function in contrast
o other series that report allograft loss, liver failure, and
eath in all patients.9,10
Among HCV-negative patients routine PCR detection of
HCV should be introduced as a standard of care during the
pretransplant period.
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